Figure 2.

Schematic representation of study protocol. The protocol entailed appropriate washout from any ongoing acromegaly medical therapy after which serum IGF-I had to be at least >1.3 times age-related ULN. All patients underwent pituitary MRI scans at baseline and completion of the study drug. An OGTT was undertaken at baseline (after washout) and again at the end of week 13. IGF-I, insulin-like growth factor 1; OGTT, oral glucose tolerance test; ULN, upper limit of normal.